Barriers to accessing cellular therapy for patients receiving care in community practices

2.

Philip

T

,

Guglielmi

C

,

Hagenbeek

A

, et al.

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma

.

N Engl J Med

.

1995

;

333

(

23

):

1540

-

1545

.

doi:10.1056/NEJM199512073332305

.

3.

Westin

JR

,

Kersten

MJ

,

Salles

G

, et al.

Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: observations from the JULIET, ZUMA-1, and TRANSCEND trials

.

Am J Hematol

.

2021

;

96

(

10

):

1295

-

1312

.

doi:10.1002/ajh.26301

.

4.

Kamdar

M

,

Solomon

SR

,

Arnason

J

, et al;

TRANSFORM Investigators

.

Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial

.

Lancet

.

2022

;

399

(

10343

):

2294

-

2308

.

doi:10.1016/S0140-6736(22)00662-6

.

5.

Westin

JR

,

Oluwole

OO

,

Kersten

MJ

, et al;

ZUMA-7 Investigators; Kite Members

.

Survival with axicabtagene ciloleucel in large B-cell lymphoma

.

N Engl J Med

.

2023

;

389

(

2

):

148

-

157

.

doi:10.1056/NEJMoa2301665

.

6.

Schuster

SJ

,

Bishop

MR

,

Tam

CS

, et al.;

JULIET Investigators

.

Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma

.

N Engl J Med

.

2019

;

380

:

45

-

56

.

doi:10.1056/NEJMoa1804980

.

7.

Nastoupil

LJ

,

Jain

MD

,

Spiegel

JY

, et al.

Axicabtagene ciloleucel (axi-cel) CD19 chimeric antigen receptor (CAR) T-cell therapy for relapsed/ refractory large B-cell lymphoma: real world experience

.

Blood

.

2018

;

132

(

suppl 1

):

91

.

doi:10.1182/blood-2018-99-114152

.

. https://tandem.confex.com/tandem/2023/meetingapp.cgi/Paper/21938.

8.

Battiwalla

M

,

Tees

M

,

Flinn

IW

, et al.

Access barriers for anti-CD19+ chimeric antigen receptor T (CAR-T) cell therapy for non-Hodgkin lymphoma (NHL) across a large community transplant and cellular therapy network, tandem meetings

. Abstract presented at: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR,

2023

9.

Sahli

B

,

Eckwright

D

,

Darling

E

, et al.

Chimeric antigen receptor T-cell therapy real-world assessment of total cost of care and clinical events for the treatment of relapsed or refractory lymphoma

.

J Clin Oncol

.

2021

;

39

(

15 suppl

).

doi:10.1200/JCO.2021.39.15_suppl.e19500

.

10.

Choe

JH

,

Abdel-Azim

H

,

Padula

WV

,

Abou-el-Enein

M.

Cost-effectiveness of axicabtagene ciloleucel and tisagenlecleucel as second-line or later therapy in relapsed or refractory diffuse large B-cell lymphoma

.

JAMA Netw Open

.

2022

;

5

(

12

):

e2245956

.

doi:10.1001/jamanetworkopen.2022.45956

.

11.

Lin

JK

,

Muffly

LS

,

Spinner

MA

,

Barnes

JI

,

Owens

DK

,

Goldhaber-Fiebert

JD

.

Cost effectiveness of chimeric antigen receptor T-cell therapy in multiply relapsed or refractory adult large B-cell lymphoma

.

J Clin Oncol

.

2019

;

37

(

24

):

2105

-

2119

.

doi:10.1200/JCO.18.02079

.

12.

Ahmed

N

,

Shahzad

M

,

Shippey

E

, et al.

Socioeconomic and racial disparity in chimeric antigen receptor T cell therapy access

.

Transplant Cell Ther

.

2022

;

28

(

7

):

358

-

364

.

doi:10.1016/j.jtct.2022.04.008

.

13.

Manz

CR

,

Porter

DL

,

Bekelman

JE

.

Innovation and access at the mercy of payment policy: the future of chimeric antigen receptor therapies

.

J Clin Oncol

.

2020

;

38

(

5

):

384

-

387

.

doi:10.1200/jco.19.01691

.

14.

Ritter

AJ

,

Goldstein

JS

,

Ayers

AA

,

Flowers

CR

.

Rural and urban patients with diffuse large B-cell and follicular lymphoma experience reduced overall survival: a National Cancer Database study

.

Leuk Lymphoma

.

2019

;

60

(

7

):

1656

-

1667

.

doi:10.1080/10428194.2018.1546855

.

15.

Han

X

,

Jemal

A

,

Flowers

CR

,

Sineshaw

H

,

Nastoupil

LJ

,

Ward

E.

Insurance status is related to diffuse large B-cell lymphoma survival: insurance and lymphoma survival

.

Cancer

.

2014

;

120

(

8

):

1220

-

1227

.

doi:10.1002/cncr.28549

.

16.

MacDougall

K

,

Day

S

,

Hall

S

, et al.

Impact of race and age and their interaction on survival outcomes in patients with diffuse large B-cell lymphoma

.

Clin Lymphoma Myeloma Leuk

.

2023

;

23

(

5

):

379

-

384

.

doi:10.1016/j.clml.2023.01.015

.

17.

Driscoll

D

,

Farnia

S

,

Kefalas

P

,

Maziarz

RT

.

Concise review: the high cost of high tech medicine: planning ahead for market access

.

Stem Cells Transl Med

.

2017

;

6

(

8

):

1723

-

1729

.

doi:10.1002/sctm.16-0487

.

18.

Maus

MV

,

Nikiforow

S.

The why, what, and how of the new FACT standards for immune effector cells

.

J Immunother Cancer

.

2017

;

5

:

36

.

doi:10.1186/s40425-017-0239-0

.

19.

Foundation for the Accreditation of Cellular Therapy (FACT)

. FACT accredited organizations for CART therapy administration

2023

. https://accredited.factglobal.org/. Accessed

3

August

2023

.

20.

Snyder

S

,

Albertson

T

,

Garcia

J

,

Gitlin

M

,

Jun

MP

.

Travel-related economic burden of chimeric antigen receptor T cell therapy administration by site of care

.

Adv Ther

.

2021

;

38

(

8

):

4541

-

4555

.

doi:10.1007/s12325-021-01839-y

.